Krystal Biotech(NASDAQ) KRYS

Krystal Biotech, Inc. NASDAQ:KRYS makes medicines that fix genetic mistakes in the body. These therapies help people with rare skin and lung diseases heal. Patients can use these treatments at home or in a clinic.

Treatments for Rare Genetic Conditions

• VYJUVEK: Topical gene therapy for dystrophic epidermolysis bullosa; accounted for all product revenue for the three-month period ended June 30, 2026.
• Ophthalmology: Redosable eye drop formulations designed to treat corneal complications and rare degenerative eye diseases.
• Respiratory: Inhaled gene therapies delivered via nebulizer for the treatment of cystic fibrosis and lung protein deficiencies.
• Oncology: Immunotherapies designed to promote immune-mediated tumor clearance through direct injection or inhalation into the lungs.
• Jeune Aesthetics: Subsidiary developing gene therapies to address skin aging and elasticity loss.

Expanding Across the Globe

• Launched VYJUVEK in the United States in 2023 following approval by the Food and Drug Administration.
• Expanded commercial operations into Germany, France, and Japan during 2025.
• Received approval for VYJUVEK in the United Kingdom in May 2026.
• Secured platform technology designations from the Food and Drug Administration for multiple pipeline candidates to streamline development.
• Advanced inhaled KB707 into phase 1/2 clinical trials for patients with lung cancer.

What Sets the Platform Apart

The company uses a proprietary platform based on modified herpes simplex virus type 1 to deliver genes to multiple organ systems. This technology allows for non-invasive applications, such as gels and inhaled mists, that can be used at home.

By the Numbers

• Product revenue reached $119.2 million for the three-month period ended June 30, 2026, up 24% year over year.
• Net income was $54.8 million for the three-month period ended June 30, 2026, up 43% year over year.
• Gross margin reached 95% for the three-month period ended June 30, 2026.
• Cumulative net product revenue since the first 2023 launch totaled $965.9 million as of June 30, 2026.
• Cash, cash equivalents, and short-term investments totaled $845.6 million as of June 30, 2026.

Bottom Line

Krystal Biotech has evolved from a clinical-stage research firm into a global commercial organization with a high-margin lead product. Its flexible genetic platform and in-house manufacturing capabilities support a broad pipeline across dermatology, ophthalmology, and respiratory medicine.